Release Time:
2026-10-20 14:59
As in vivo immune cell engineering, targeted nucleic acid delivery, and in vivo CAR-T development advance, delivering mRNA and other payloads to specific T-cell populations has become an important research priority.
CD8⁺ T cells play key roles in antitumor immunity and immune regulation, making CD8 an attractive target for nanoparticle-mediated delivery. CD8-targeted nanocarriers are being investigated for delivering mRNA to T cells, with potential applications in in vivo T-cell engineering.
For targeted lipid nanoparticles (tLNPs), however, identifying an antibody that binds CD8 is only the first step.
A targeting ligand suitable for tLNP development must meet additional requirements:
- Does it recognize CD8 displayed on the cell surface?
- How does its binding vary between cells expressing CD8αα and CD8αβ?
- Is target-binding activity retained after conjugation to LNPs?
- How does conjugation affect particle size, uniformity, and stability?
- Can the resulting tLNPs recognize target cells and support functional payload delivery?
To address these questions, Levostar Biotech is launching a validation series following anti-CD8 VHH candidates through successive stages of evaluation for tLNP applications.
From Candidate Sequences to Potential tLNP Ligands
The antibody discovery program began with camelid mRNA immunization against CD8-related antigens, using Levostar’s proprietary adjuvant developed for camelid immunization. Interim assessments showed increased antigen-specific antibody titers.
Following antibody discovery and sequence analysis, we identified 20 candidate VHH sequences from each of two antigen systems—CD8αα and CD8αβ—yielding 40 candidates for further evaluation.
These sequences provide a starting point for development. Their suitability as tLNP targeting ligands must be established experimentally.
Our evaluation workflow includes recombinant expression, antibody quality assessment, cell-binding assays, LNP conjugation, particle characterization, and functional testing. Each stage addresses a different aspect of candidate performance, with particular emphasis on whether target recognition and delivery potential are retained after LNP conjugation.

Figure 1. Sequence clustering analysis of a subset of anti-CD8A VHH candidates derived from an individual camelid.
Initial Cell-Binding Assessment in Two Jurkat Models
The initial screening stage evaluated candidate binding to Jurkat cells expressing CD8A or CD8AB using flow cytometry.
Most candidates showed binding to Jurkat-CD8A cells, Jurkat-CD8AB cells, or both. However, the percentage of positive cells and the binding profiles across the two models varied among candidates.

Figure 2. Overview of flow cytometry results for candidate VHHs tested against Jurkat-CD8A and Jurkat-CD8AB cells.
These results provide an initial basis for comparing candidates and prioritizing further experiments. For example, subsequent studies will examine which candidates show consistent binding across both models, which exhibit different binding profiles, and whether these patterns are associated with sequence features or performance in downstream applications.
Cell binding alone does not establish suitability for tLNP development. These initial results do not demonstrate that a candidate will retain activity after conjugation or enable functional delivery. They represent the first stage of a broader validation process.
Following Candidates Through tLNP Development
Starting with this initial set of 40 VHH candidates, the series will share experimental findings as the program progresses.
Planned topics include:
- Expression and quality: recombinant production and assessment of antibody quality.
- Cell binding: comparison of target recognition across relevant cell models.
- Animal-related studies: additional evaluation as supported by the study design and development stage.
- LNP conjugation: assessment of candidate compatibility with the conjugation process.
- Particle characterization: evaluation of the resulting tLNPs, including nanoflow cytometry analysis.
- Post-conjugation performance: testing of target recognition and functional payload delivery.
The series will document how candidates progress through these stages, including those selected for further testing, those requiring additional investigation, and those discontinued because they do not meet the requirements for the intended tLNP application.
This approach will help distinguish promising cell-binding candidates from VHHs that also perform effectively as LNP-conjugated targeting ligands.
What Comes Next?
The initial cell-binding assessment of the first 40 candidates is complete. The next phase will investigate which candidates retain favorable properties through further characterization and LNP conjugation.
Our goal is to progressively identify anti-CD8A VHHs with suitable expression, consistent target binding, compatibility with LNP conjugation, and potential for targeted delivery.
Follow the series as we move from candidate sequences to experimental evidence for CD8-targeted LNP development.